D.E. Shaw & Co
CDLX icon

D.E. Shaw & Co’s Cardlytics CDLX Stock Holding History

D.E. Shaw & Co’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,710
Closed -$58.1K – 4269
2023
Q1 		$58.1K Sell
1,710
-12,680
-88% -$662K ﹤0.01% 4028
2022
Q4 		$832K Sell
14,390
-3,240
-18% -$200K ﹤0.01% 3561
2022
Q3 		$1.66M Buy
17,630
+13,610
+339% +$1.94M ﹤0.01% 3164
2022
Q2 		$897K Buy
+4,020
New +$1.35M ﹤0.01% 3711
2021
Q2 		– Sell
-550
Closed -$603K – 4766
2021
Q1 		$603K Buy
+550
New +$726K ﹤0.01% 3416

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $122M AUM 11.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

D.E. Shaw & Co's CDLX Position: Q1 2026 in Review

D.E. Shaw & Co sold out of Cardlytics (CDLX) in Q1 2026, closing a stake of 2,621 shares — an estimated $30.1K sold.

D.E. Shaw & Co first reported a position in CDLX in Q4 2019 and held it in 25 quarters. The position peaked at $25.6M in Q4 2019. 59 funds tracked by Wall St. Rank hold CDLX as of Q1 2026.

  • D.E. Shaw & Co reported no remaining Cardlytics position as of Q1 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 2,621 Cardlytics shares in Q1 2026, an estimated $30.1K.
  • D.E. Shaw & Co first reported a position in Cardlytics in Q4 2019 and held it in 25 quarters.
  • D.E. Shaw & Co's Cardlytics position peaked at $25.6M in Q4 2019.
  • 59 funds tracked by Wall St. Rank held Cardlytics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.